GE Acquires Breast Ultrasound Developer U-Systems
GE Healthcare axquires U-Systems Inc., developer of the Automated Breast Ultrasound, a system used as a supplement to mammography for asymptomatic women with dense breasts and no prior interventions.
GE Healthcare announced last week the acquisition of U-Systems Inc., developer of a breakthrough ultrasound system approved for breast cancer screening.
U-Systems’ somo•v® Automated Breast Ultrasound (ABUS) was approved by the FDA in September as an adjunct to mammography for asymptomatic women with dense breasts and no prior breast interventions. The companies did not disclose the financial terms of the acquisition.
“The combination of U-Systems, Inc. and GE Healthcare uniquely positions GE to offer U.S. healthcare providers and their patients the most comprehensive portfolio of breast care innovations on the market - from screening to diagnosis to monitoring,” Tom Gentile, president and CEO of GE Healthcare Systems, said in a statement.
Studies have shown that women with dense breast tissue are at a greater risk of breast cancer compared with those with little or no dense tissue.
"The worldwide resources of GE Healthcare will allow us to expand and accelerate our efforts to commercialize the recently FDA-Approved somo•v® ABUS,” Ron Ho, U-Systems president and CEO, said in a statement. “With our combined resources and capabilities, we have the opportunity to make a significant impact on breast cancer detection and patient outcomes around the world.”
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
What New Research Reveals About Novice Use of AI-Guided Cardiac Ultrasound
April 4th 2025In a study recently presented at the American College of Cardiology (ACC) conference, researchers found that novice use of AI-guided cardiac ultrasound after an AI-enabled electrocardiogram increased the positive predictive value for reduced left ventricular ejection fraction (LVEF) or aortic valve stenosis by 33 percent.
